Adage Capital Partners
ARCT icon

Adage Capital Partners’s Arcturus Therapeutics ARCT Stock Holding History

Adage Capital Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-450,000
Closed -$15.2M – 871
2024
Q1 		$15.2M Buy
+450,000
New +$15.9M 0.03% 518
2020
Q3 		– Sell
-100,000
Closed -$4.67M – 755
2020
Q2 		$4.67M Buy
+100,000
New +$3.45M 0.01% 632

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners's ARCT Position: Q2 2024 in Review

Adage Capital Partners sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 450,000 shares — an estimated $15.2M sold.

Adage Capital Partners first reported a position in ARCT in Q2 2020 and held it in 2 quarters. The position peaked at $15.2M in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Adage Capital Partners reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Adage Capital Partners sold 450,000 Arcturus Therapeutics shares in Q2 2024, an estimated $15.2M.
  • Adage Capital Partners first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 2 quarters.
  • Adage Capital Partners's Arcturus Therapeutics position peaked at $15.2M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Adage Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.